Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2

Immunotherapies targeting programmed cell death protein 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), dramatically improve the survival of melanoma patients. However, only ∼40% of treated patients demonstrate a clinical response to single-agent anti-PD-1 therapy. An intact tumor re...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Na, Formisano, Luigi, Gonzalez-Ericsson, Paula I., Sanchez, Violeta, Dean, Phillip T., Opalenik, Susan R., Sanders, Melinda E., Cook, Rebecca S., Arteaga, Carlos L., Johnson, Douglas B., Balko, Justin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975601/
https://www.ncbi.nlm.nih.gov/pubmed/29872580
http://dx.doi.org/10.1080/2162402X.2018.1438106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975601/
https://www.ncbi.nlm.nih.gov/pubmed/29872580
http://dx.doi.org/10.1080/2162402X.2018.1438106

Ejemplares similares